[Circulating Neuregulin-1 and Chronic Heart Failure with Preserved Ejection]

Area of Science:

• Cardiology
• Molecular Biology
• Pathophysiology

Background:

• Chronic heart failure with preserved ejection fraction (CHFpEF) presents a significant clinical challenge due to high morbidity and mortality.
• Current understanding implicates systemic inflammation and endothelial dysfunction in CHFpEF pathogenesis, leading to myocardial fibrosis and diastolic dysfunction.
• Lack of early diagnostic markers and effective therapies necessitates research into underlying mechanisms and novel therapeutic targets.

Purpose of the Study:

• To investigate the role of the Neuregulin-1 (NRG-1)/ErbB4 signaling pathway in the early stages of CHFpEF.
• To evaluate the therapeutic potential of NRG-1 in improving cardiac function and remodeling in CHFpEF.
• To explore the anti-inflammatory and antifibrotic effects of NRG-1 in the context of CHFpEF.

Main Methods:

• Review of current literature on CHFpEF pathogenesis and the NRG-1/ErbB4 system.
• Analysis of preclinical and clinical (phases II and III) data regarding recombinant NRG-1 therapy.
• Examination of emerging evidence on the molecular effects of NRG-1, including anti-inflammatory and antifibrotic actions.

Main Results:

• The NRG-1/ErbB4 system is activated early in CHFpEF, enhancing cardiomyocyte resistance to oxidative stress.
• Recombinant NRG-1 therapy has demonstrated improvements in myocardial contractility and left ventricular (LV) reverse remodeling in preclinical and clinical studies.
• Recent findings suggest NRG-1 possesses anti-inflammatory and antifibrotic properties relevant to CHFpEF.

Conclusions:

• The NRG-1/ErbB4 pathway is a key player in the early stages of CHFpEF and warrants further investigation.
• NRG-1 therapy holds potential for improving cardiac function and remodeling in CHFpEF patients.
• Targeting the NRG-1 system may offer a novel therapeutic strategy for CHFpEF, addressing its inflammatory and fibrotic components.